Chang Gung Memorial Hospital Researchers Detail Research in Colon Cancer [Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan].

After propensity score matching, 261 patients were included in three groups: no-treatment, half-year treatment, and one-year treatment. Keywords: Adjuvant Chemotherapy; Cancer; Chemotherapy; Colon Cancer; Colorectal Research; Combined Modality Therapy; Drugs and Therapies; Enzymes and Coenzymes; Formyltetrahydrofolates; Gastroenterology; Health and Medicine; Leucovorin; Leucovorin Therapy; Oncology; Pharmaceuticals; Risk and Prevention EN Adjuvant Chemotherapy Cancer Chemotherapy Colon Cancer Colorectal Research Combined Modality Therapy Drugs and Therapies Enzymes and Coenzymes Formyltetrahydrofolates Gastroenterology Health and Medicine Leucovorin Leucovorin Therapy Oncology Pharmaceuticals Risk and Prevention 177 177 1 10/16/23 20231016 NES 231016 2023 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on colon cancer have been presented. According to the news editors, the research concluded: "This study suggests that tegafur/uracil plus leucovorin is a feasible adjuvant chemotherapy regimen for patients with stage II colorectal cancer after curative surgical treatment. [Extracted from the article]

Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)